摘要
目的探讨奥扎格雷钠在肺心病急性加重期的临床治疗效果及影响血液高凝的机制。方法选取2010年1月—2011年7月在我科治疗的肺心病急性加重期患者90例,按心功能情况分为对照组和观察组各45例,并设一健康人群组(健康组),对照组给予常规治疗,观察组在常规治疗的基础上加用奥扎格雷钠,在治疗前后观察两组患者的凝血机制、症状及体征变化。结果凝血机制改善情况:观察组治疗后血栓素B2(TXB2)、6-keto-PGF1α改善明显,差异具有统计学意义(P<0.05),对照组改善不明显,差异无统计学意义(P>0.05)。治疗后观察组与对照组比较观察组中TXB2、6-keto-PGF1α各数值明显优于对照组,差异具有统计学意义(P<0.05)。治疗前观察组和对照组TXB2、6-keto-PGF1α与健康组差异明显(P<0.05),治疗后各项数值均有不同程度改善,但是差异仍然较为明显(P<0.05)。治疗后观察组PaCO2和PaO2较对照组改善更为明显(P<0.05)。两组疗效比较,观察组有效率明显高于对照组,差异具有统计学意义(P<0.05)。结论奥扎格雷钠有效抑制了血小板聚集,使肺部小血管扩张,改善了急性期患者体内血液高凝状态和避免肺小动脉血栓形成。
Objective To investigate the clinical therapeutic effect of Ozagrel sodium on pulmonary heart disease（PHD） in acute exacerbation period,and its mechanisms that affect hypercoagulability. Methods Ninety patients with acute exacerbation period PHD in our department from January 2010 to July 2011 were divided into control group（45 cases） and observation group（45 cases） according to theirs cardiac function and set up a health group.Control group were treated with conventional therapy,observation group were treated by conventional therapy and Ozagrel sodium.The changes of clotting mechanisms,symptoms and physical sign were observed before and after treatment. Results Improvement of clotting mechanisms： thromboxane B2（TXB2） and 6-keto-PGF1α were improved significantly,the difference has statistical significance（P0.05）.No obvious improvement in the control group and no statistical significance in difference（P0.05）.Pre-treatment TXB2 and 6-keto-PGF1α in observation group were significantly better than in control group,the difference has statistical significance（P0.05）.Compared with health group,there were significant differences of TXB2 and 6-keto-PGF1α in control group and observation group before treatment（P0.05）.After treatment,the values were improved in varying degrees,but the differences still obvious（P0.05）,PaCO2 and PaO2 in observation group were improved more significantly than in control group（P0.05）.Compared the therapeutic effect between two groups,effective rate in observation group was higher than in control group,the difference has statistical significance（P0.05）. Conclusion Ozagrel sodium can effectively inhibit platelet aggregation,dilate Pulmonary blood vessels,improve hypercoagulability duiring acute exacerbation period of PHD and avoid thrombosis in small pulmonary artery.
出处
《临床军医杂志》
CAS
2012年第6期1393-1396,共4页
Clinical Journal of Medical Officers
关键词
奥扎格雷钠
肺心病
急性加重期
Ozagrel sodium
pulmonary heart disease
acute exacerbation period
